RETRACTED: Clinical and radiographic evaluation of osseotite‐expanded platform implants related to crestal bone loss: a 10‐year study

Abstract Objective The aim of this prospective clinical study was to evaluate the survival rates at 10 years of expanded platform implants placed in the anterior zone of the maxilla and immediately restored with single crowns. Materials and methods Implants incorporating the platform‐switching conce...

Full description

Saved in:
Bibliographic Details
Published inClinical oral implants research Vol. 25; no. 3; pp. 352 - 358
Main Authors Calvo‐Guirado, José Luis, Gómez‐Moreno, Gerardo, Delgado‐Ruiz, Rafael A., Maté Sánchez de Val, José E., Negri, Bruno, Ramírez Fernández, María P.
Format Journal Article
LanguageEnglish
Published 01.03.2014
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Objective The aim of this prospective clinical study was to evaluate the survival rates at 10 years of expanded platform implants placed in the anterior zone of the maxilla and immediately restored with single crowns. Materials and methods Implants incorporating the platform‐switching concept were placed in fresh extraction sockets in the maxillary arch, with each patient receiving a provisional restoration immediately after implant placement. After 15 days, final screwed restorations were inserted. Mesial and distal bone heights were evaluated using digital radiography on the day following implant placement and at 1, 5, 7, and 10 years. Primary stability was measured with resonance frequency analysis ( RFA ) using the O sstell M entor device. Eighty‐six implants were placed in 32 men and 32 women ranging in age between 29 and 60 (mean, 39.64 ± 5.16 years). Results Marginal bone loss from implant collar to bone crest between baseline and 10 years follow‐up was 1.01 mm ± 0.22. Mesial site crestal bone loss ranged from 3.57 mm ± 1.1 at baseline to 3.77 mm ± 0.7 at 10‐year. Distal site crestal bone loss ranged from 3.49 mm ± 0.8 at baseline to 3.73 mm ± 0.7 at 10 year. Conclusion The platform‐switched implants remained stable over the course of 10 years and had an overall survival rate of 97.1%.
ISSN:0905-7161
1600-0501
DOI:10.1111/clr.12134